Moderna plans to lay off 10% of workforce to cut costs

Moderna (MRNA.O) announced plans to reduce its global workforce by approximately 10% by year-end, a strategic move to cut costs amidst declining COVID-19 vaccine sales. This action is part of a broader initiative to slash operating expenses by up to $1.7 billion by 2027, targeting a range of $4.7-$5 billion, and complements other cost-saving measures like R&D scaling and supplier renegotiations, while the company maintains its goal for eight new product approvals within three years.

Analysis

Moderna (MRNA) is undertaking a significant operational restructuring, highlighted by a planned 10% reduction in its global workforce by year-end. This measure is a direct response to the decline in sales of its COVID-19 vaccines and is a key component of a broader, multi-year strategy to reduce operating costs by as much as $1.7 billion by 2027. The company is implementing a multi-faceted approach to achieve this, including scaling down R&D as specific trials conclude, renegotiating supplier agreements, and optimizing manufacturing costs, with a targeted operating expense range of $4.7 billion to $5 billion for 2027. While these actions are defensive and reflect the negative sentiment surrounding the company's near-term revenue outlook, management is attempting to counterbalance this by reiterating a crucial forward-looking target: securing eight new product approvals within the next three years. This signals a strategic pivot from a pandemic-level operational scale to a more sustainable model focused on its long-term R&D pipeline.

Key Decisions for Investors

• Investors should closely monitor the company's execution on its cost-cutting initiatives, as achieving the targeted $1.7 billion in savings by 2027 is critical for stabilizing margins amidst falling COVID-related revenue.
• The focus for valuation shifts decisively to the non-COVID pipeline; therefore, tracking clinical trial progress and regulatory milestones for the eight targeted product approvals over the next three years is paramount.
• While the restructuring is a necessary response to market conditions, it introduces execution risk, so it may be prudent to assess the impact of these cuts on R&D productivity and overall company morale before adjusting a long-term position.